Comparison 11.

Serious adverse events

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 SAEs in the varenicline trials	29	15370	Risk Ratio (M‐H, Fixed, 95% CI)	1.25 [1.04, 1.49]
2 SAEs in the varenicline trials, exc post‐treat events	26	15000	Risk Ratio (M‐H, Fixed, 95% CI)	1.25 [1.02, 1.52]
3 Neuropsychiatric SAEs (not deaths)	23	8955	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.57, 1.19]
4 Cardiac SAEs, including deaths	21	8587	Risk Ratio (M‐H, Fixed, 95% CI)	1.36 [0.91, 2.04]